<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398240</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-568</org_study_id>
    <nct_id>NCT02398240</nct_id>
  </id_info>
  <brief_title>Brentuximab for Newly Diagnosed Hodgkin Disease</brief_title>
  <official_title>A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitchell Cairo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well
      tolerated and effective in children, adolescents and young adults with all stages of newly
      diagnosed Hodgkin lymphoma (HL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if this combination of chemoimmunotherapy is safe to administer. (Adverse events)</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events will be monitored each cycle to determine if there are any events related possibly, probably or definitely related to study therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the response rate</measure>
    <time_frame>1 year</time_frame>
    <description>disease evaluations will be performed after the 2nd, 4th and 6th cycles.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Adcetris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Days: 1 and 15 Dose: 25 mg/m2/dose.</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Doxil, Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Days: 2 and 16 Dose: 375 mg/m2/dose.</description>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal Serum creatinine based on age or creatinine clearance &gt;60 ml/min/1.73 m2 or an
             equivalent radioisotope glomerular filtration rate (GFR) as determined by the
             institutional normal range.

          -  Direct bilirubin &lt; 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT
             (ALT) &lt;3 x ULN

          -  Shortening fraction &gt;27% by echocardiogram, or

          -  Ejection fraction of &gt;50% by radionuclide angiogram or echocardiogram.

          -  For patients age 1-16 years, Lansky score of ≥60.

          -  For patients &gt; 16 years, Karnofsky score of ≥60.

          -  No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal
             irradiation (&lt;1000cGy) for superior vena cava (SVC) syndrome.

        Exclusion Criteria:

          -  Females who are pregnant (positive HCG) or lactating.

          -  Karnofsky &lt;60% or Lansky &lt;60% if less than 16 years of age.

          -  Age ≤1 year or &gt;29.99 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Hochberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Hochberg, MD</last_name>
    <phone>9145942132</phone>
    <email>jessica_hochberg@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mitchell Cairo, MD</last_name>
    <phone>9145942150</phone>
    <email>mitchell_cairo@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell S Cairo, MD</last_name>
      <phone>914-594-2150</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Harrison, MSN</last_name>
      <phone>6172857844</phone>
      <email>lauren_harrison@nymc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Executive Vice Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

